Florida Cancer Specialists & Research Institute introduces liquid biopsy test
This test may be used to evaluate colorectal, lung, prostate, breast, and blood cancers.
Liquid biopsy represents an advancement in cancer diagnosis and treatment, utilising a simple draw of blood to test for circulating tumour DNA (ctDNA).
The introduction of liquid biopsy at FCS underscores the practice's focus on expanding its comprehensive genomic testing offerings, thereby improving diagnostic accuracy, guiding physicians in treatment decisions, and the patients' clinical outcomes.
FCS claims to have broadened its testing options for the 250 physicians serving more than 102,000 individuals across Florida, since the introduction of next-generation sequencing (NGS) offerings at its centralised in-house laboratory in 2021.
The practice has seen over 4.2 million annual visits and recently surpassed over 16,000 molecular tests processed at its Fort Myers lab facility.
FCS genetics laboratory associate director Jennifer Gass said: 'Liquid biopsy is especially effective for providing genetic information quickly for various types of advanced cancers to help physicians assess and better target treatments that may work best and monitor patient response.
'Additionally, because it is minimally invasive and easy to repeat on an ongoing basis, liquid biopsy is significantly more comfortable for patients.'
The expansion of the NGS testing menu at the FCS includes the addition of homologous recombination deficiency (HRD) testing, which analyses tumour DNA to determine potential treatment responses to poly (ADP-ribose) polymerase (PARP) inhibitors.
This class of drugs specifically targets cancer cells.
Other additions include a small heme NGS panel that identifies mutations related to myeloproliferative neoplasms and a quantitative assay for monitoring BCR-ABL gene fusions post-treatment in specific blood cancers.
"Florida Cancer Specialists & Research Institute introduces liquid biopsy test" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
26-million-year-old fossil with sharp teeth reveals fierce origins of modern whales
A fossil pulled from Victoria's Surf Coast has revealed a very different kind of whale, one built for speed, sight, and killing power. Measuring just over two metres, Janjucetus dullardi had large forward-facing eyes, a short snout, and razor-edged teeth. It prowled the seas 26 million years ago, long before its gentle, filter-feeding relatives evolved. Scientists at Museums Victoria's Research Institute say the discovery offers a rare glimpse into the earliest stages of baleen whale evolution, showing the family's roots in active, sharp-toothed predators. Beach find leads to breakthrough The partial skull, complete with teeth and ear bones, was spotted in June 2019 by local resident Ross Dullard during a walk along the coast. Aware of its scientific potential, he handed the specimen to Museums Victoria. The research team later honoured him by naming the species Janjucetus dullardi. 'This kind of public discovery and its reporting to the museum is vital,' said Dr Erich Fitzgerald, senior curator of vertebrate palaeontology at Museums Victoria Research Institute and senior author of the study. He said Dullard's contribution 'has unlocked an entire chapter of whale evolution we've never seen before.' The fossil turned out to be from a juvenile measuring just over two metres long. It belonged to a group called mammalodontids, a short-lived family of early whales that thrived only during the Oligocene Epoch, around 30 to 23 million years ago. Lead author Ruairidh Duncan, a PhD student at the institute and Monash University, described the creature vividly: 'It's essentially a little whale with big eyes and a mouth full of sharp, slicing teeth. Imagine the shark-like version of a baleen whale – small and deceptively cute, but definitely not harmless.' Rewriting the history of whale evolution Only three other mammalodontid species have been confirmed worldwide, two of them also from Victoria. This latest find is the first to preserve both the teeth and inner ear structures in fine detail. These features are vital for reconstructing how early whales sensed their surroundings, hunted, and moved through the water. MicroCT scans revealed delicate components inside the ear bones, including the cochlea. These results offer clues about how Janjucetus dullardi could navigate and detect prey in ancient seas. 'This fossil opens a window into how ancient whales grew and changed,' said Fitzgerald, noting it shows 'how evolution shaped their bodies as they adapted to life in the sea.' The remains came from the Jan Juc Formation, a fossil-rich site dating to a period of global warmth and rising sea levels. The region is now regarded as one of the world's emerging centres for studying early whale evolution. Fitzgerald said understanding how prehistoric whales adapted to warm oceans could help predict how marine life might cope with today's climate changes. 'This region was once a cradle for some of the most unusual whales in history, and we're only just beginning to uncover their stories,' he said. Researchers expect more finds from the Surf Coast in the coming years, as well as new insights from specimens already stored in the Museums Victoria State Collection. Lynley Crosswell, CEO and Director of Museums Victoria, emphasised the broader impact of the work: 'The findings demonstrate the power of our collections to unlock stories that change the way we understand life on Earth.' She credited public generosity and scientific expertise for helping the institute make 'globally significant contributions to evolutionary research.' Solve the daily Crossword
Yahoo
4 days ago
- Yahoo
This ancient Indian seashell trick can help with sleep apnea — and reduce snoring
Shell shock! Nearly 54 million US adults are believed to suffer from obstructive sleep apnea (OSA), which occurs when muscles in your throat relax and repeatedly block your airway, causing you to stop breathing as you sleep. Besides disrupted sleep and snoring, OSA can raise the risk of high blood pressure, heart disease, Type 2 diabetes, stroke and car crashes. 'The standard treatment for OSA is a continuous positive airway pressure machine, or CPAP, which keeps the patient's airway open by blowing air through a facemask throughout the night,' said Dr. Krishna K. Sharma from the Eternal Heart Care Centre and Research Institute in Jaipur, India. 'While effective, many patients find it uncomfortable and struggle to use it consistently.' Sharma is conch-fident that an ancient Indian practice known as shankh blowing can ease OSA symptoms without the hassle of a costly machine. He led a small study that reported that OSA patients who regularly blew into a conch for six months had fewer breathing interruptions at night and more alertness during the day. 'In my clinical practice, several patients reported feeling more rested and experiencing fewer symptoms after regularly practicing shankh blowing — a traditional yogic breathing exercise involving exhaling through a conch shell,' Sharma said. 'These observations led us to design a scientific study to rigorously test whether this simple, ancient practice could serve as a meaningful therapy for people with OSA.' Thirty people between 19 and 65 years old were divided into two groups — 16 blew through a conch shell while 14 engaged in a deep breathing exercise. The conch group underwent training and daily practice sessions at home before the study commenced. Eternal Heart tracked the participants, who had moderate OSA, from May 2022 to January 2024. They were monitored while sleeping and asked about their sleep quality and daytime sleepiness. After six months, the conch group was 34% less sleepy during the daytime than the deep breathing group. Medical testing showed that the conch group participants had an average of four or five fewer episodes where their breathing stopped during sleep. They also had higher levels of oxygen in their blood at night. The conch-lusions were published this week in the ERJ Open Research journal. 'For people living with OSA, especially those who find CPAP uncomfortable, unaffordable or inaccessible, our findings offer a promising alternative,' Sharma said. 'Shankh blowing is a simple, low-cost breathing technique that could help improve sleep and reduce symptoms without the need for machines or medication.' Blowing shankhs can cost anywhere from $20 to over $100. The theory is that shankh blowing strengthens muscles crucial to maintaining an open airway during sleep. Dr. Sophia Schiza — a professor of respiratory and sleep medicine at the University of Crete in Greece and head of the European Respiratory Society group on sleep-disordered breathing — called it an 'intriguing study.' 'A larger study will help provide more evidence for this intervention, which could be of benefit as a treatment option or in combination with other treatments in selected OSA patients,' said Schiza, who was not involved in this research. Sharma is planning a larger trial involving several hospitals, a longer study period and more severe forms of OSA. The team wants to further explore how shankh blowing affects airway muscle tone, oxygen levels and sleep and compare it against treatments like CPAP. Losing weight, exercising and abstaining from alcohol can also help OSA, along with oral devices, a different sleep position and surgery in severe cases. Solve the daily Crossword
Medscape
08-08-2025
- Medscape
Other GU Cancers Share Germline Mutation Rates Seen in Ovarian Cancer
This transcript has been edited for clarity. Hello. I'm Dr Maurie Markman, from City of Hope. I'd like to discuss a very interesting and controversial topic. The paper I'm discussing is 'Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multisite Single-Institution Prospective Study,' published in the Journal of Urology . It has been well recognized for over a decade that patients with ovarian cancer need to have germline testing, independent of whether they have a family history of that particular cancer because we identified particular mutations — BRCA mutations, BRCA1 and BRCA2 — that may not be evident in the family by history but are very relevantpotentially for cascade testing of their family members later. Also, of course, in that setting, there are therapeutic implications for the use of PARP inhibitors. Increasingly, the discussion is about more universal testing for patients with breast cancer because of the incidences of BRCA and other mutations that are both relevant for treatment and for the question of genetic counseling for other members of the family. What about other tumor types? What about genitourinary (GU) cancers, as identified here? Should one take patients with all different kinds of GU tumors — prostate cancer, bladder cancer, kidney cancers, typically — and say there's a role for universal germline testing when a patient has been identified as having one of these cancers? To address this question, the group at the Mayo Clinic undertook comprehensive germline testing, examining for pathogenic germline variants at several sites from April 2018 to March 2020. This was a greater than 80-gene panel that was offered to patients. Today, that testing may be really quite different, but at that point it was greater than 80 genes that were tested for potential abnormality. A total of 601 patients enrolled with GU cancers. Again, this was across the sites and with GU cancers, regardless of a family history. There were 358 patients with prostate cancer, 106 with bladder cancer, and 137 with kidney cancer. Surprisingly, a majority of these patients, 86%, were male. Here is the important bottom line. Pathogenic germline variants, most with risk of high penetrance, were identified in 82 individuals, or 14% of the population. First, they were seen in almost the same percentage in kidney, bladder, and prostate cancer, and that 14% is not that far off. In fact, it's quite similar to the statement about ovarian cancer in terms of the overall population — 14% of the patients with GU cancer. Importantly, at this time, based on these data, fully 67% (or 2 of 3) patients had abnormalities that were potentially actionable. "Actionable" could mean a variety of things. It could mean there may be a therapy involved. It could mean that we need to talk to members of the family. They were not like, 'Oh, that's interesting, but there's nothing we can do about it.' For 2 out of 3, they could actually do something actionable. Importantly, of those 82 patients, 35% had at least one relative undergo cascade testing to examine for that variant. The bottom line here is that more than 1 of 8 patients in this unselected group of patients with GU cancers had a variant finding that was potentially pathogenic at the germline level. This would argue for — although there is going to be controversy and we need more data — universal testing, certainly of GU tumors, and one might ask for other tumor types. We need more data to confirm that. This would obviously be an extensive, new universal recommendation with costs associated with it, but this paper certainly raises that question that needs to be further examined. Thank you for your attention.
